Cell Line for Producing Recombinant Glycoproteins with Di-Antennary N-Glycans, Methods Using the Same, and Recombinant Glycoproteins
AssigneeCevec Pharmaceuticals GmbH
InventorsSilke Wissing, Jens Wölfel, Nicole Faust, Helmut Kewes
Life of this patent
Estimating the term…
Abstract
The present invention relates to a genetically modified cell line with reduced expression of GnTIVa/b and/or GnTV, a method for the production of glycoproteins having N-glycans with a reduced number of tri- and/or tetra-antennary N-glcyans using said cell line, and respective glycoproteins.
Claims16
A cell line that is genetically modified to reduce the expression of at least one of GnTIVa/b and GnTV.
A recombinant glycoprotein having N-glycans with a significantly increased proportion of di-antennary N-glycans when compared to the same recombinant glycoprotein expressed in a cell line with non-reduced expression of GnTIVa/b and/or GnTV.
Dependencies are inferred from the claim text.